Drugs that contain Dalfampridine
1. Ampyra patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5540938 | ACORDA | Formulations and their use in the treatment of neurological diseases |
Jul, 2018
(5 years ago) | |
| US9918973 | ACORDA | Sustained release aminopyridine composition |
Dec, 2024
(7 months from now) | |
| US8663685 | ACORDA | Sustained release aminopyridine composition |
Jan, 2025
(8 months from now) | |
| US8440703 | ACORDA | Methods of using sustained release aminopyridine compositions |
Apr, 2025
(11 months from now) | |
| US8354437 | ACORDA | Method of using sustained release aminopyridine compositions |
Dec, 2026
(2 years from now) | |
| US8007826 | ACORDA | Sustained release aminopyridine composition |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE) | Jan 22, 2017 |
| New Chemical Entity Exclusivity(NCE) | Jan 22, 2015 |
NCE-1 date: 22 January, 2014
Market Authorisation Date: 22 January, 2010
Treatment: Improvement of walking in patients with multiple sclerosis (ms)
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of AMPYRA before it's drug patent expiration?
More Information on Dosage
AMPYRA family patents
